{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Habel JR"],"funding":["Research Grants Council of Hong Kong","Monash University","AINSE Ltd.","The University of Melbourne","National Health and Medical Research Council","Australian Research Council"],"pagination":["e1010337"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8929706"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["18(3)"],"pubmed_abstract":["HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide broadly cross-reactive immunity to distinct influenza strains and subtypes, including influenza A, B and C viruses, understanding CD8+ T cell immunity to influenza viruses across prominent HLA types is needed to rationally design a universal influenza vaccine and generate protective immunity especially for high-risk populations. As only a handful of HLA-A*11:01-restricted CD8+ T cell epitopes have been described for influenza A viruses (IAVs) and epitopes for influenza B viruses (IBVs) were still unknown, we embarked on an epitope discovery s"],"journal":["PLoS pathogens"],"pubmed_title":["HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people."],"pmcid":["PMC8929706"],"funding_grant_id":["Melbourne Research Scholarship","T11-712/19-N","BDI PhD scholarship","1145033","1137739","1122524","1091516","Postgraduate Research Award (PGRA),","Melbourne International Research Scholarship and Melbourne International Fee Remission Scholarship","FL160100049","1173871","1085018","1071916","1159272"],"pubmed_authors":["Nelson J","Purcell AW","Nguyen AT","Rowntree LC","Szeto C","Rossjohn J","Illing PT","Gras S","Mifsud NA","Loh L","Rockman S","Habel JR","Hensen L","Clemens EB","Davies J","Tong SYC","Chen W","Kedzierska K","Miller A"],"additional_accession":[]},"is_claimable":false,"name":"HLA-A*11:01-restricted CD8+ T cell immunity against influenza A and influenza B viruses in Indigenous and non-Indigenous people.","description":"HLA-A*11:01 is one of the most prevalent human leukocyte antigens (HLAs), especially in East Asian and Oceanian populations. It is also highly expressed in Indigenous people who are at high risk of severe influenza disease. As CD8+ T cells can provide broadly cross-reactive immunity to distinct influenza strains and subtypes, including influenza A, B and C viruses, understanding CD8+ T cell immunity to influenza viruses across prominent HLA types is needed to rationally design a universal influenza vaccine and generate protective immunity especially for high-risk populations. As only a handful of HLA-A*11:01-restricted CD8+ T cell epitopes have been described for influenza A viruses (IAVs) and epitopes for influenza B viruses (IBVs) were still unknown, we embarked on an epitope discovery s","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Mar","modification":"2026-06-02T16:19:22.771Z","creation":"2025-02-19T01:53:35.468Z"},"accession":"S-EPMC8929706","cross_references":{"pubmed":["35255101"],"doi":["10.1371/journal.ppat.1010337"]}}